VSS Capital Partners, a private investment firm investing in the healthcare, education, and business services industries, made a growth capital investment in Eximia Research Network, a Dover, Delaware -based multi-therapeutic, clinical trial research company that serves pharmaceutical companies, biotech companies and contract research organizations (“CROs”).
Financial terms of the private transaction were not disclosed.
Eximia is led by CEO Dr. Ella Grach, a leading industry executive who previously served as the CEO of M3 Wake Research, one of North America’s largest fully integrated network of clinical research sites. As part of the launch, Eximia has formed a strategic partnership with Sundance Clinical Research, a St. Louis, MO-based research site with a high-quality operating track record dating back to its founding in 2005.
VSS and Dr. Grach formed Eximia with a mission to advance clinical trial delivery and improve lives by expanding access to clinical research as a care option for all. Eximia leverages centralized services to support its network of research sites and serves as a strategic partner to leading pharmaceutical, biotech and CROs.
Eximia, in a close partnership with clinical trial sponsors, accelerates the drug approval process by enhancing its key delivery components, focusing on patient centric recruitment and engagement, rapid study start up and data integrity.
FinSMEs
04/10/2023